Biologics in the treatment of Sjogren's syndrome, systemic l... : Current Opinion in
Rheumatology Biologics in the treatment of Sjogren's syndrome, systemic lupus …

Introduction Despite setbacks in clinical trials for systemic lupus erythematosus (SLE), three
drugs have been approved for SLE and lupus nephritis (LN) treatment in the past decade …

Systemic lupus erythematosus (SLE) is a chronic autoimmune multisystem disease with a
variable presentation and manifestations ranging from mild to severe or even life …

Sjogren's syndrome (keratoconjunctivis sicca) is a relatively common disorder with
incidence of∼ 0.5% of adult women. It has both local (ocular and oral) features as well as …

Lupus nephritis (LN) is a chronic and devastating complication of systemic lupus
erythematosus. Despite advances in our understanding of LN and the availability of effective …

Introduction: Systemic lupus erythematosus (SLE) is a multi-systemic disease characterized
by an unpredictable disease course and periods of remission and flare, leading to organ …

New therapeutics in systemic lupus erythematosus : Current Opinion in Rheumatology New
therapeutics in systemic lupus erythematosus : Current Opinion in Rheumatology Log in or …

Systemic lupus erythematosus (SLE) is a ripe area for drug development. There are great
unmet needs, especially for those with lupus nephritis, in which good responses occur only …

Systemic lupus erythematosus (SLE) is a prototypic inflammatory autoimmune disorder
characterized by multisystem involvement and fluctuating disease activity. Symptoms range …

Introduction Systemic lupus erythematosus (SLE) is a chronic disease that is potentially fatal.
There is no cure for SLE and the medications used are associated with toxic side effects. In …